Home > Press > Targeted nanoparticles incorporating siRNA offer promise for cancer treatment
Abstract:
The use of targeted nanoparticles offers promising techniques for cancer treatment. Researchers in the laboratory of Mark E. Davis at the California Institute of Technology have been using small interfering RNA (siRNA), sometimes known as silencing RNA, to "silence" specific genes that are implicated in certain malignancies. One of the primary challenges associated with this type of therapy is delivering the therapeutic agent into the body and then to the tumor in a safe and effective manner. By using targeted nanoparticles, researchers have demonstrated that systemically delivered siRNA can slow the growth of tumors in mice without eliciting the toxicities often associated with cancer therapies. The results of this research are being presented this week at the NSTI Nanotech 2007 Conference in Santa Clara, CA.
The Caltech researchers have incorporated siRNA into nanoparticles that are formed completely by self-assembly, characterized the behavior of these nanoparticles and studied their safety and efficacy in mice.
Using extensive physicochemical and biological characterization, the investigators are able to estimate the composition of individual nanoparticles and to correlate the nanoparticle structure with its biological function. This quantitative approach provides unique insights into the design of more effective nanoparticle carriers.
According to the lead author of the study, Derek W. Bartlett, "Safe and effective delivery remains perhaps the greatest impediment to the clinical realization of small interfering RNA (siRNA) in cancer therapy. Formation of siRNA nanoparticles using cyclodextrin-containing polycations is one of the most promising strategies for systemic siRNA delivery, and such nanoparticles are expected to enter Phase I clinical trials by late 2007. Our most recent work examines the impact of various dosing schedules and surface modifications on the efficacy of these siRNA nanoparticles in preclinical cancer models. By combining the experimental data with a mathematical model of siRNA-mediated gene silencing, we illustrate several practical considerations that we believe will be directly relevant to the clinical application of siRNA-based therapeutics in cancer therapy."
The presentation is "Characterization and in vivo efficacy of targeted nanoparticles for systemic siRNA delivery to tumors" by D.W. Bartlett and M.E. Davis, from the California Institute of Technology. It will be presented at the NSTI Nanotech 2007 conference in Santa Clara, CA on May 21, 2007, 4:40 PM, Great America 3, Santa Clara Convention Center.
####
For more information, please click here
Contacts:
Jami Walker
314-579-3342
Copyright © Elsevier Health Sciences
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Discoveries
Chemical reactions can scramble quantum information as well as black holes April 5th, 2024
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Utilizing palladium for addressing contact issues of buried oxide thin film transistors April 5th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Events/Classes
Researchers demonstrate co-propagation of quantum and classical signals: Study shows that quantum encryption can be implemented in existing fiber networks January 20th, 2023
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||